Intra-Cellular [ITCI] vs Zoetis [ZTS] Detailed Stock Comparison

Intra-Cellular Therapies Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Intra-Cellular Therapies Inc. wins in 5 metrics, Zoetis Inc. wins in 13 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Intra-Cellular Therapies Inc. Zoetis Inc. Better
P/E Ratio (TTM) -183.15 19.58 Zoetis Inc.
Price-to-Book Ratio 12.20 15.04 Intra-Cellular Therapies Inc.
Debt-to-Equity Ratio 1.48 279.59 Intra-Cellular Therapies Inc.
PEG Ratio 507.19 2.81 Zoetis Inc.
EV/EBITDA -112.19 13.96 Zoetis Inc.
Profit Margin (TTM) -10.97% 28.24% Zoetis Inc.
Operating Margin (TTM) -14.66% 34.69% Zoetis Inc.
EBITDA Margin (TTM) N/A 34.69% N/A
Return on Equity -8.58% 65.99% Zoetis Inc.
Return on Assets (TTM) -6.96% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $-73.50M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 92.68% -51.58% Intra-Cellular Therapies Inc.
Price-to-Sales Ratio (TTM) 20.63 5.26 Zoetis Inc.
Enterprise Value $13.04B $56.75B Zoetis Inc.
EV/Revenue Ratio 19.15 6.00 Zoetis Inc.
Gross Profit Margin (TTM) 89.76% 70.17% Intra-Cellular Therapies Inc.
Revenue per Share (TTM) $7 $21 Zoetis Inc.
Earnings per Share (Diluted) $-0.73 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.46 0.97 Intra-Cellular Therapies Inc.
Short % of Float N/A 4.06% N/A

Intra-Cellular Therapies Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

ITCI
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Intra-Cellular Therapies Inc.0.00%N/AN/AN/AN/AN/A
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Intra-Cellular Therapies Inc.92.68%104.13%700.67%449.92%632.61%632.61%
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%

Performance & Financial Health Analysis: Intra-Cellular Therapies Inc. vs Zoetis Inc.

MetricITCIZTS
Market Information
Market Cap i$14.05B$49.75B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,749,3682,727,710
90 Day Avg. Volume i2,309,5093,835,940
Last Close$131.87$167.10
52 Week Range$64.09 - $131.98$139.70 - $200.33
% from 52W High-0.08%-16.59%
All-Time High$131.98 (Mar 31, 2025)$249.27 (Dec 27, 2021)
% from All-Time High-0.08%-32.96%
Growth Metrics
Quarterly Revenue Growth0.51%0.03%
Quarterly Earnings Growth0.51%0.04%
Financial Health
Profit Margin (TTM) i-0.11%0.28%
Operating Margin (TTM) i-0.15%0.35%
Return on Equity (TTM) i-0.09%0.66%
Debt to Equity (MRQ) i1.48279.59
Cash & Liquidity
Book Value per Share (MRQ)$10.81$7.84
Cash per Share (MRQ)$9.42$5.48
Operating Cash Flow (TTM) i$-73,177,000$2.90B
Levered Free Cash Flow (TTM) i$-63,549,624$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Intra-Cellular Therapies Inc. vs Zoetis Inc.

MetricITCI (May 17, 2025)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i-183.1519.58
Forward P/E i507.1915.61
PEG Ratio i507.192.81
Price to Sales (TTM) i20.635.26
Price to Book (MRQ) i12.2015.04
Market Capitalization
Market Capitalization i$14.05B$49.75B
Enterprise Value i$13.04B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i19.156.00
Enterprise to EBITDA i-112.1913.96
Risk & Other Metrics
Beta i0.460.97
Book Value per Share (MRQ) i$10.81$7.84

Financial Statements Comparison: Intra-Cellular Therapies Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricITCI (2024)ZTS (2025)
Revenue/Sales i680.50M9.47B
Cost of Goods Sold i56.96M2.67B
COGS % of Revenue i8.4%28.2%
Gross Profit i623.54M6.80B
Gross Margin i91.6%71.8%
Research & Development i236.12M698.00M
Operating Income (EBIT) i-116.72M3.60B
Operating Margin i-17.2%38.0%
EBITDA i-116.21M4.17B
EBITDA Margin i-17.1%44.1%
Pre-Tax Income i-74.20M3.36B
Pre-Tax Income % of Revenue i-10.9%35.5%
Income Tax i473,000687.00M
Income Tax % of Revenue i0.1%7.3%
Net Income (Profit) i-74.68M2.67B
Profit Margin i-11.0%28.2%

Balance Sheet & Liquidity Metrics

MetricITCI (2024)ZTS (2025)
Cash & Equivalents i306.95M2.31B
Total Current Assets i1.31B6.77B
Total Current Assets % of Revenue i192.1%71.5%
Total Current Liabilities i205.70M2.24B
Total Current Liabilities % of Revenue i30.2%23.6%
Long-Term Debt i12.75M9.24B
Long-Term Debt % of Revenue i1.9%97.6%
Total Shareholders Equity i1.15B3.33B
Retained Earnings i-1.69B13.74B
Retained Earnings % of Revenue i-248.6%145.2%
Property, Plant & Equipment i14.90M288.00M

Cash Flow Statement Comparison

MetricITCI (2024)ZTS (2025)
Operating Cash Flow i-63.27M2.78B
Operating Cash Flow % of Revenue i-9.3%29.3%
Capital Expenditures i-322,000N/A
Free Cash Flow i-73.50M2.28B
FCF Margin i-10.8%24.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase iN/A-3.24B

Short Interest & Institutional Ownership Analysis

MetricITCIZTS
Shares Short iN/A15.12M
Short Ratio iN/A3.60
Short % of Float iN/A4.06%
Shares Outstanding i106.24M424.93M
Float Shares i104.82M421.29M
% Held by Insiders i2.48%0.15%
% Held by Institutions i96.45%101.50%
% Held by Public i1.07%-1.65%

Dividend Analysis & Yield Comparison: Intra-Cellular Therapies Inc. vs Zoetis Inc.

MetricITCIZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026